Ignite Creation Date:
2025-12-24 @ 5:08 PM
Ignite Modification Date:
2026-03-11 @ 9:09 PM
Study NCT ID:
NCT02325050
Status:
COMPLETED
Last Update Posted:
2017-06-14
First Post:
2014-12-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
Sponsor:
Janssen Vaccines & Prevention B.V.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Healthy | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Healthy | View |
| None | Ebola viruses | View |
| None | Ebola Viral Disease (EVD) | View |
| None | Filoviruses | View |
| None | monovalent vaccine | View |
| None | Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga … | View |
| None | Modified Vaccinia Virus Ankara - Bavarian Nordic (MVA-BN) Filo-vector | View |
| None | Safety | View |
| None | Immunogenicity | View |